DiaMedica Therapeutics In... (DMAC)
NASDAQ: DMAC
· Real-Time Price · USD
5.78
-0.25 (-4.15%)
At close: Aug 18, 2025, 3:59 PM
5.65
-2.25%
After-hours: Aug 18, 2025, 06:58 PM EDT
-4.15% (1D)
| Bid | 5.64 |
| Market Cap | 298.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -8.38 |
| Forward PE | -5.84 |
| Analyst | Strong Buy |
| Ask | 6.48 |
| Volume | 177,441 |
| Avg. Volume (20D) | 313,979 |
| Open | 5.93 |
| Previous Close | 6.03 |
| Day's Range | 5.68 - 6.06 |
| 52-Week Range | 3.19 - 6.82 |
| Beta | 1.24 |
About DMAC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DMAC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DMAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
-13.02%
DiaMedica Therapeutics shares are trading lower fo...
Unlock content with
Pro Subscription
3 weeks ago · businesswire.com
DiaMedica Therapeutics Announces Closing of $30.1 Million Private PlacementMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
2 months ago · businesswire.com
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, ...